MiMedx Group (MDXG) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Market overview and reimbursement environment

• Placenta-derived allografts are used in chronic wound care and surgical applications, with a strong presence in hospitals, private offices, and adjacent care settings.

• Recent years have seen a surge in Medicare spending for wound care products, rising from less than $500 million in 2020 to $4 billion in 2023, largely due to price manipulation by new market entrants exploiting regulatory loopholes.

• Medicare administrative carriers have proposed local coverage determinations (LCDs) to address runaway spending, but implementation timing and format remain uncertain.

• Congressional and CMS attention is focused on reforming reimbursement, aiming to create a more investable and sustainable market.

• Ensuring patient access during reimbursement reform is critical, as untreated chronic wounds can lead to severe outcomes like amputation with high mortality rates.

Strategic initiatives and M&A activity

• Strategic priorities include diversifying the product portfolio into xenograft and synthetic categories, expanding in the surgical market, and enhancing customer intimacy.

• The acquisition of HELIOGEN marks the first entry into non-human tissue products, specifically a bovine-derived collagen particulate for complex wound healing.

• Financial improvements include moving from break-even to profitability, refinancing debt, and building cash reserves to support future investments.

• Broader M&A opportunities are being considered to extend presence in wound care and surgical markets, leveraging new platforms and regulatory pathways.

Clinical data and research focus

• Ongoing investment in research is prioritized, with recent high-profile publications highlighting the potential of human amnion chorion membranes to reduce fibrosis and scarring in surgical procedures.

• Products are being used in a growing range of surgical applications, and randomized controlled trials (RCTs) like EpiFix are underway to further validate efficacy.

• The company maintains a strong scientific evidence base and is confident in real-world outcomes translating to clinical trial success.